secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALATIN TECHNOLOGIES INC (PTN)
CIK:        0000911216
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0001654954-23-011637
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palatin completes enrollment in Phase 3 dry eye study (PL9643); 570 patients enrolled, topline expected Q4 2023
--------------------------------------------------------------------------------

- PL9643 MELODY-1 Phase 3 study enrolled 570 patients with moderate-to-severe dry eye disease.
- Topline data anticipated by end of Q4 2023; interim analysis of first 120 patients showed safety and efficacy.
- Assuming positive results, NDA submission to FDA expected mid-2025 after two more Phase 3 studies in 2024-2025.
- Company highlighted PL9643's novel mechanism of action and differentiated profile vs. current DED treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/911216/000165495423011637/0001654954-23-011637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/911216/000165495423011637/ptn_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-011637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer